Meet with our product experts in one-on-one virtual sessions and get a deep insight into our API Pharma Products offerings.
Our experts will answer your questions, provide advice, and help you understand our product better.
Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products – Dr. Reddy’s is an active pharma API manufacturing company and pharmaceutical ingredient supplier for foremost formulators and offers a portfolio of products and services, including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations.
Our API business caters to leading innovator and generic companies across the US, Europe, Latin America, Japan, Korea, and other emerging markets. With deep technical strengths in the development of complex APIs such as steroids, peptides, complex long chain synthesis and oncology we consistently deliver high-quality APIs.
As a pharmaceutical API manufacturer, our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s operates in markets across the globe and top API manufactures in USA. Our major markets include – USA, Europe, India, Russia, and other CIS countries.
About Dr. Reddy’s API Business
150+ APIs
8 Manufacturing
Sites
More than 1150 drug master files
across global markets
50+ Pipeline molecules
(Filed + under development)
State-of-the-art R&D centers
in India, U.K., U.S. & Netherlands
Over 1300+ research scientists
working on various projects
Our Achievements
11/11/2021
Dr. Reddy's API team is a 2021 winner in - API Supplier of the year at Global generics & Biosimilars awards
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
10/11/2021
Dr. Reddy's at CPHI 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
03/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2020
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of 'Excellence in Pharma: Sustainability'
Resources
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor indicated for treating hypertension to lower blood pressure. ACE inhibitors inhibit the angiotensin-converting enzyme (ACE) actions, thereb
Azacitidine is a nucleoside metabolic inhibitor indicated to continue treating adult patients with acute myeloid leukemia. In addition, it is indicated for use in adult patients with acute myeloid leu
Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective peripheral H1-receptor antagonist activity. Fexofenadine Hydrochloride is indicated for:
Eribulin Mesylate (Halaven®) is a microtubule inhibitor indicated to treat patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens to treat
Dr. Reddy’s is well-positioned to support its API customers with APIs and services for peptides with extensive peptide therapeutics development capabilities, state-of-the-art process facilities supp
Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist, with 94% sequence homology to human GLP-1 indicated as an adjunct to diet and exercise to improve glycaemic control in adults wit
Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signalling pathway. Enzalutamide has been shown to inhibit androgen binding to androgen receptors c
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostases, such as DNA transcription, cell cy
Remdesivir is the First treatment approved by the US FDA for the treatment of COVID-19 in adult and paediatric patients (12 years or older, and weighing at least 40 kg) that require hospitalization.
Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 selectively and irreversibly via a covalent binding mechanism. Abir
Gemcitabine Hydrochloride is an analog of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycyti
